338 related articles for article (PubMed ID: 15624495)
41. The pathogenesis of transthyretin tissue deposition: lessons from transgenic mice.
Buxbaum J; Tagoe C; Gallo G; Reixach N; French D
Amyloid; 2003 Aug; 10 Suppl 1():2-6. PubMed ID: 14640034
[TBL] [Abstract][Full Text] [Related]
42. Activation of ERK1/2 MAP kinases in familial amyloidotic polyneuropathy.
Monteiro FA; Sousa MM; Cardoso I; do Amaral JB; Guimarães A; Saraiva MJ
J Neurochem; 2006 Apr; 97(1):151-61. PubMed ID: 16515552
[TBL] [Abstract][Full Text] [Related]
43. [Immunological and serological laboratory tests: transthyretin].
Ando Y
Rinsho Byori; 2005 Jun; 53(6):554-7. PubMed ID: 16026084
[TBL] [Abstract][Full Text] [Related]
44. Chapter 17: Transthyretin: an enhancer of nerve regeneration.
Fleming CE; Mar FM; Franquinho F; Sousa MM
Int Rev Neurobiol; 2009; 87():337-46. PubMed ID: 19682646
[TBL] [Abstract][Full Text] [Related]
45. [Amyloid neuropathy].
Ikegawa S
Rinsho Shinkeigaku; 1990 Dec; 30(12):1371-3. PubMed ID: 1966018
[TBL] [Abstract][Full Text] [Related]
46. Familial amyloid polyneuropathy.
Barreiros AP; Galle PR; Otto G
Dig Dis; 2013; 31(1):170-4. PubMed ID: 23797140
[TBL] [Abstract][Full Text] [Related]
47. Liver transplantation and anemia in familial amyloidosis ATTR V30M.
Beirão I; Lobato L; Costa PM; Fonseca I; Silva M; Bravo F; Cabrita A; Porto G
Amyloid; 2007 Mar; 14(1):33-7. PubMed ID: 17453623
[TBL] [Abstract][Full Text] [Related]
48. A transgenic rat with the human ATTR V30M: a novel tool for analyses of ATTR metabolisms.
Ueda M; Ando Y; Hakamata Y; Nakamura M; Yamashita T; Obayashi K; Himeno S; Inoue S; Sato Y; Kaneko T; Takamune N; Misumi S; Shoji S; Uchino M; Kobayashi E
Biochem Biophys Res Commun; 2007 Jan; 352(2):299-304. PubMed ID: 17126291
[TBL] [Abstract][Full Text] [Related]
49. The transthyretin gene is expressed in Schwann cells of peripheral nerves.
Murakami T; Ohsawa Y; Zhenghua L; Yamamura K; Sunada Y
Brain Res; 2010 Aug; 1348():222-5. PubMed ID: 20547140
[TBL] [Abstract][Full Text] [Related]
50. Recent progress in the understanding and treatment of transthyretin amyloidosis.
Sekijima Y
J Clin Pharm Ther; 2014 Jun; 39(3):225-33. PubMed ID: 24749898
[TBL] [Abstract][Full Text] [Related]
51. Effect of serum amyloid P component level on transthyretin-derived amyloid deposition in a transgenic mouse model of familial amyloidotic polyneuropathy.
Murakami T; Yi S; Maeda S; Tashiro F; Yamamura K; Takahashi K; Shimada K; Araki S
Am J Pathol; 1992 Aug; 141(2):451-6. PubMed ID: 1497094
[TBL] [Abstract][Full Text] [Related]
52. Deposition of transthyretin amyloid is not accelerated by the same amyloid in vivo.
Wei L; Kawano H; Fu X; Cui D; Ito S; Yamamura K; Ishihara T; Tokuda T; Higuchi K; Maeda S
Amyloid; 2004 Jun; 11(2):113-20. PubMed ID: 15478467
[TBL] [Abstract][Full Text] [Related]
53. Systemic delivery of transthyretin siRNA mediated by lactosylated dendrimer/α-cyclodextrin conjugates into hepatocyte for familial amyloidotic polyneuropathy therapy.
Hayashi Y; Mori Y; Higashi T; Motoyama K; Jono H; Sah DW; Ando Y; Arima H
Amyloid; 2012 Jun; 19 Suppl 1():47-9. PubMed ID: 22519861
[TBL] [Abstract][Full Text] [Related]
54. Steady turnover of amyloid fibril proteins in gastric mucosa after liver transplantation in familial amyloid polyneuropathy.
Tsuchiya-Suzuki A; Yazaki M; Sekijima Y; Kametani F; Ikeda S
Amyloid; 2013 Sep; 20(3):156-63. PubMed ID: 23826783
[TBL] [Abstract][Full Text] [Related]
55. Presence of N-glycosylated transthyretin in plasma of V30M carriers in familial amyloidotic polyneuropathy: an escape from ERAD.
Teixeira AC; Saraiva MJ
J Cell Mol Med; 2013 Mar; 17(3):429-35. PubMed ID: 23387326
[TBL] [Abstract][Full Text] [Related]
56. Transthyretin-derived amyloid deposition on the gastric mucosa in domino recipients of familial amyloid polyneuropathy liver.
Takei Y; Gono T; Yazaki M; Ikeda S; Ikegami T; Hashikura Y; Miyagawa S; Hoshii Y
Liver Transpl; 2007 Feb; 13(2):215-8. PubMed ID: 17029284
[TBL] [Abstract][Full Text] [Related]
57. [Effect of liver trasplantation on familial amyloidotic polyneuropathy (FAP) and its limt].
Ando Y
Rinsho Shinkeigaku; 2011 Nov; 51(11):1138-41. PubMed ID: 22277510
[TBL] [Abstract][Full Text] [Related]
58. Amyloid deposits in transthyretin-derived amyloidosis: cleaved transthyretin is associated with distinct amyloid morphology.
Bergström J; Gustavsson A; Hellman U; Sletten K; Murphy CL; Weiss DT; Solomon A; Olofsson BO; Westermark P
J Pathol; 2005 Jun; 206(2):224-32. PubMed ID: 15810051
[TBL] [Abstract][Full Text] [Related]
59. Efficiency of silencing RNA for removal of transthyretin V30M in a TTR leptomeningeal animal model.
Gonçalves P; Martins H; Costelha S; Maia LF; Saraiva MJ
Amyloid; 2016 Dec; 23(4):249-253. PubMed ID: 27884058
[TBL] [Abstract][Full Text] [Related]
60. Suppression of choroid plexus transthyretin levels by antisense oligonucleotide treatment.
Benson MD; Smith RA; Hung G; Kluve-Beckerman B; Showalter AD; Sloop KW; Monia BP
Amyloid; 2010 Jun; 17(2):43-9. PubMed ID: 20462362
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
